Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. April 2026 08:30 ET | Quelle: AINewsWire

Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value

AUSTIN, Texas, April 09, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: Pharmaceutical manufacturing is entering a period of structural transformation as regulators impose increasingly...
09. April 2026 08:30 ET | Quelle: Annovis Bio Inc.

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...
09. April 2026 08:30 ET | Quelle: Onconetix, Inc.

Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson

Vinci Enables Realbotix Robots to Recognize People, Recall Conversations, and Track Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of...
09. April 2026 08:05 ET | Quelle: NKGen Biotech, Inc.

NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit

SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and...
09. April 2026 08:00 ET | Quelle: Assembly Biosciences, Inc.

Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026

– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation –– Phase 1b data from ABI-1179 accepted for late-breaker poster presentation...
09. April 2026 08:00 ET | Quelle: Nautilus Biotechnology Inc.

Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026

SEATTLE, April 09, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will...
09. April 2026 08:00 ET | Quelle: Valitor, Inc.

Valitor to Participate in the 25th Annual Needham Virtual Healthcare Conference

BERKELEY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced that chief executive officer Gregory...
09. April 2026 07:30 ET | Quelle: Plus Therapeutics Inc.

Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and...
09. April 2026 07:05 ET | Quelle: Unicycive Therapeutics, Inc.

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
09. April 2026 07:00 ET | Quelle: Seres Therapeutics, Inc.

Seres Therapeutics to Present at CARB-X Investor Day

CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at...

Vorherige Seite

Nächste Seite